Your browser doesn't support javascript.
loading
Rac1/PAK1 signaling contributes to bone cancer pain by Regulation dendritic spine remodeling in rats.
Xu, Lingfei; Yang, Long; Wu, Yan; Wan, Xinxin; Tang, Xihui; Xu, Yuqing; Chen, Qingsong; Liu, Yuepeng; Liu, Su.
Afiliação
  • Xu L; Jiangsu Province Key Laboratory of Anesthesiology, Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, NMPA Key Laboratory for Research and Evaluation of Narcotic and Psychotropic Drugs, 505488Xuzhou Medical University, Jiangsu, China.
  • Yang L; Jiangsu Province Key Laboratory of Anesthesiology, Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, NMPA Key Laboratory for Research and Evaluation of Narcotic and Psychotropic Drugs, 505488Xuzhou Medical University, Jiangsu, China.
  • Wu Y; Jiangsu Province Key Laboratory of Anesthesiology, Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, NMPA Key Laboratory for Research and Evaluation of Narcotic and Psychotropic Drugs, 505488Xuzhou Medical University, Jiangsu, China.
  • Wan X; Department of Anesthesiology, 505488The Affiliated Hospital of Xuzhou Medical University, Jiangsu, China.
  • Tang X; Department of Anesthesiology, 66506Nanjing Drum Tower Hospital, Jiangsu, China.
  • Xu Y; Jiangsu Province Key Laboratory of Anesthesiology, Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, NMPA Key Laboratory for Research and Evaluation of Narcotic and Psychotropic Drugs, 505488Xuzhou Medical University, Jiangsu, China.
  • Chen Q; Department of Anesthesiology, 505488The Affiliated Hospital of Xuzhou Medical University, Jiangsu, China.
  • Liu Y; Jiangsu Province Key Laboratory of Anesthesiology, Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, NMPA Key Laboratory for Research and Evaluation of Narcotic and Psychotropic Drugs, 505488Xuzhou Medical University, Jiangsu, China.
  • Liu S; Department of Anesthesiology, 505488The Affiliated Hospital of Xuzhou Medical University, Jiangsu, China.
Mol Pain ; 19: 17448069231161031, 2023.
Article em En | MEDLINE | ID: mdl-36938611
ABSTRACT
Bone cancer pain (BCP) is severe chronic pain caused by tumor metastasis to the bones, often resulting in significant skeletal remodeling and fractures. Currently, there is no curative treatment. Therefore, insight into the underlying mechanisms could guide the development of mechanism-based therapeutic strategies for BCP. We speculated that Rac1/PAK1 signaling plays a critical role in the development of BCP. Tumor cells implantation (TCI) into the tibial cavity resulted in bone cancer-associated mechanical allodynia. Golgi staining revealed changes in the excitatory synaptic structure of WDR (Wide-dynamic range) neurons in the spinal cord, including increased postsynaptic density (PSD) length and thickness, and width of the cleft. Behavioral and western blotting test revealed that the development and persistence of pain correlated with Rac1/PAK1 signaling activation in primary sensory neurons. Intrathecal injection of NSC23766, a Rac1 inhibitor, reduced the persistence of BCP as well as reversed the remodeling of dendrites. Therefore, we concluded that activation of the Rac1/PAK1 signaling pathway in the spinal cord plays an important role in the development of BCP through remodeling of dendritic spines. Modulation of the Rac1/PAK1 pathway may be a potential strategy for BCP treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Dor do Câncer Limite: Animals Idioma: En Revista: Mol Pain Assunto da revista: BIOLOGIA MOLECULAR / NEUROLOGIA / PSICOFISIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Dor do Câncer Limite: Animals Idioma: En Revista: Mol Pain Assunto da revista: BIOLOGIA MOLECULAR / NEUROLOGIA / PSICOFISIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China